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Phospholipases A2 (PLA2s) are important components of Bothrops snake venoms, that can induce several
effects on envenomations such as myotoxicity, inhibition or induction of platelet aggregation and edema.
It is known that venomous and non-venomous snakes present PLA2 inhibitory proteins (PLIs) in their
blood plasma. An inhibitory protein that neutralizes the enzymatic and toxic activities of several PLA2s
from Bothrops venoms was isolated from Bothrops alternatus snake plasma by afﬁnity chromatography
using the immobilized myotoxin BthTX-I on CNBr-activated Sepharose. Biochemical characterization of
this inhibitory protein, denominated aBaltMIP, showed it to be a glycoprotein with Mr ofw24,000 for the
monomeric subunit. CD spectra of the PLA2/inhibitor complexes are considerably different from those
corresponding to the individual proteins and data deconvolution suggests that the complexes had
a relative gain of helical structure elements in comparison to the individual protomers, which may
indicate a more compact structure upon complexation. Theoretical and experimental structural studies
performed in order to obtain insights into the structural features of aBaltMIP indicated that this molecule
may potentially trimerize in solution, thus strengthening the hypothesis previously raised by other
authors about snake PLIs oligomerization.
 2010 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
Accidents caused by venomous snakes represent a signiﬁcant
public health problem especially in tropical countries, considering
the frequency of occurrence and the mortality they induce [1].
The constitution of snake venoms is complex, containing more
than 20 different components and with more than 90% of their dry
weight corresponding to proteins. Among the protein content of
these venoms, there is a wide variety of enzymes, and the non-
protein part is composed by carbohydrates, lipids, metals, amino
acids, nucleotides, among other constituents [2].ses Clínicas, Toxicológicas e
as de Ribeirão Preto, Uni-
Brazil. Tel.: þ55 16 602 4714;
s-Filho), andreims@fcfrp.usp.
under the Elsevier OA license.Phospholipases A2 (PLA2s, E.C. 3.1.1.4) are enzymes that catalyze
the hydrolysis of 2-acyl ester bonds of 3-sn-phospholipids,
releasing free fatty acids and lysophosphatides [3]. These enzymes
are widely distributed in nature and are found in the interior and
exterior of cells [4], pancreatic secretions [5], inﬂammatory
exudates [6] and arthropod and snake venoms [7].
Independently of their primary catalytic function, the PLA2s can
induce several pharmacological and/or toxic effects, such as myo-
necrosis, anticoagulation, inhibition of platelet aggregation,
neurotoxicity, cardiotoxicity, arterial hypotension, increase of the
microvascular permeability and edema formation [8e13]. Besides,
PLA2s are also associated with muscular necrosis, an important
local effect induced by some snake venoms, which may lead to
permanent loss of tissue and function that may result in the
amputation of the affected limb [14].
Considering these factors, several studies have been carried out
in search of natural inhibitors of snake venom PLA2s. Some authors
already described the presence of these inhibitors in the plasma of
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[17], in plants as Withania somnifera [18], Cordia verbenacea [19],
Piper umbellatum and Piper peltatum [20], Bauhinia forﬁcata [21],
and also in the plasma of snakes [22e25].
Plasma of venomous and non-venomous snakes possesses PLA2
inhibitory proteins, denominated PLIs [25]. According to several
studies, these PLIs are responsible for the natural resistance of
snakes against the toxic components of their own venoms, or to
those of other species [23,26e29].
The PLA2 inhibitors can be classiﬁed into three types (a, b and g),
according to structural aspects [30]. Nevertheless, their mecha-
nisms of action remain unknown, which incites new structural and
functional studies. a-type inhibitors (aPLIs) isolated from the
plasma of Crotalinae snakes are acidic glycoproteins constituted of
more than two subunits and possess sequential similarity to the
carbohydrate recognition domain (CRD) of C-type lectins [31]. At
the moment, it is believed that the mechanism by which aPLIs
neutralize the toxic effects of snake venom PLA2s involves the CRD
region, particularly CRD4, which recognizes and binds to these
enzymes, preventing their enzymatic activity on the cell membrane
[32].
The present study reports the isolation of a phospholipase A2
inhibitory protein from Bothrops alternatus snake plasma (aBalt-
MIP) and also highlights interesting biochemical, structural and
functional features related to this molecule.2. Materials and methods
2.1. Materials
A specimen of B. alternatus snake was supplied by the serpenta-
rium of Universidade de São Paulo, Ribeirão Preto. Blood was
collected in0.38% sodiumcitrate and centrifuged for 10minat450 g
and room temperature for obtainment of the corresponding plasma,
which was then lyophilized and stored at 20 C. Another specimen
of the same specieswas obtained from the serpentariumof Fundação
Ezequiel Dias, Belo Horizonte,MG. At the time of sampling, the snake
was euthanized with CO2 before dissection. Liver samples were
collected, quickly frozen in liquid nitrogen and stored at80 C until
RNA extraction. Animal carewas in accordancewith the guidelines of
the Brazilian College for Animal Experimentation (COBEA) and was
approved by the Committee for Ethics in Animal Utilization of Uni-
versidade de São Paulo (No. 09.1.329.53.3) and IBAMA (No. 11781-1).
Activated Sepharose 4B-CNBr and Sephacryl S-200 were purchased
from Amersham Pharmacia Biotech (GE-Healthcare) and the oligo-
nucleotides fromGibco BRL. All other reagents used for chemical and
biological characterization were acquired from Sigma Chem. Co.,
BioLab, Gibco BRL or Mediatech.2.2. Phospholipases A2 and synthetic peptides
BthA-I-PLA2, bothropstoxins I and II (BthTX-I and -II) from
Bothrops jararacussu, piratoxins I and III (PrTX-I and -III) from
Bothrops pirajai and crotoxin B (CB) from Crotalus durissus terriﬁcus
were isolated by ion-exchange chromatography on CM-Sepharose
using 0.05 M ammonium bicarbonate (AMBIC) buffer, pH 8.0, as
previously described [33,34]. Peptides were synthesized by Fmoc
chemistry, with native endings by a commercial provider (Chiron
Mimotopes, Victoria, Australia or PepMetric Technologies Inc., Van-
couver, Canada). Their estimated molecular masses were in agree-
mentwith corresponding calculated values,withﬁnal purity levels of
at least 95% by RP-HPLC analysis. Peptides were kept dry at 20 C,
anddissolved in 0.12MNaCl, 40mMsodiumphosphate (PBS), pH7.2,
immediately before being tested for their activities. Peptides werederived from the C-terminal region 115e129 of the Lys49 PLA2e like
BthTX-I (pepBthTX-I ¼ 115KKYRYHLKPFCKK129).
2.3. Puriﬁcation of the inhibitor
aBaltMIP was isolated from B. alternatus blood plasma as
follows. B. jararacussu BthTX-I (40 mg) was coupled to 10 ml of
CNBr-activated Sepharose 4B as described by the manufacturer. It
was then settled in a 1.0  8.0 cm column and equilibrated with
0.1 M phosphate buffer, pH 7.2. B. alternatus plasma (10 ml) was
diluted with the same buffer (50 ml, buffer 1) and applied on the
column at a ﬂow rate of 2.0 ml/min. Absorbance was recorded at
280 nm and sample was reﬂuxed for 2 h followed by an extensive
washing with the same buffer. The PLA2-bound inhibitor was then
eluted with 0.1 M glycine-HCl buffer, pH 2.8 (buffer 2), and the pH
of the eluted samplewas immediately adjusted to pH 7.0 with 0.5M
TriseHCl buffer, pH 8.0. The aBaltMIP was desalted and concen-
trated using a YM-10,000 Amicon membrane by successive wash-
ings with 0.05 M AMBIC, pH 8.0, aliquoted in 1.0 ml portions,
lyophilized and stored at 20 C [25,35].
2.4. Biochemical characterization
Polyacrylamide gel electrophoresis was performed in the pres-
ence of sodium dodecyl sulfate (SDSePAGE), following a previously
described method [36]. A PPSQ-33A (Shimadzu) automatic
sequencer was used for the N-terminal sequencing. The phenyl-
thiohydantoin (PTH) amino acids were identiﬁed by comparing
their retention times with the 20 PTH-amino acid of the standard
mixture. The peptides obtained were compared with the sequences
of other related proteins in the SWISS-PROT/TREMBL databases
using the FASTA and BLAST programs. To conﬁrm the purity degree,
reverse-phase HPLC was performed using a C18 column of
4.6  100 mm (GE-Healthcare). C18 column was equilibrated with
solvent A (0.1% triﬂuoroacetic acid), and eluted with a concentra-
tion gradient of solvent B (70% acetonitrile, 0.1% triﬂuoroacetic acid)
from 0 to 100%, at a ﬂow rate of 1 ml/min during approximately
90 min. The peaks were monitored by absorbance at 280 nm.
2.5. Inhibitory effect of aBaltMIP on biological activities
of snake venom PLA2s
2.5.1. Inhibition of anticoagulant and PLA2 activities
The ability of aBaltMIP to inhibit the enzymatic activity of the
basic Asp49 PLA2s BthTX-II, BthA-I-PLA2, PrTX-III and CB was
evaluated by previous incubation of these toxins (25 mg) with the
inhibitor at different molar ratios. Anticoagulant activity was
assayed on platelet poor plasma and the PLA2 assay on agarose gel
containing red blood cells and egg yolk phospholipids [25,33,37].
2.5.2. Inhibition of cytotoxic activity
Cytotoxicity induced by PLA2s (20 mg) in the presence or absence
of aBaltMIP was assayed on endothelial cells (tEnd) according to
Angulo et al. [38]. In order to establish the 100% cytotoxic level for
tEnd cells, 150 ml of 0.1% triton X-100 in culture mediumwere incu-
bated with the cells. For the 0% reference, the culture medium was
used alone. After 3 h of incubation at 37 C, aliquots of 100 ml from the
supernatants were assayed for lactate dehydrogenase (LDH) activity
according to the Sigma 500 colorimetric method. Results were
expressed as the percentage of cytotoxicity relative to LDH released
by the detergent alone. In order to measure the cytotoxic activity
uponmuscular cells,mousemyoblast cell lines (C2C12)were assayed
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) staining, as described byMosmann [39]. Cellswere disposed in
96-well plates at a density of 1  105 cells per well. After 24 h of
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without different concentrations of indicated compounds, as
pepBthTX-I (100 mg), pepBthTX-I/aBaltMIP (1:1, molar ratio) and
aBaltMIP (100 mg), was added to the wells and incubated for 24 h.
2.5.3. Inhibition of myotoxicity
In vivo myotoxic activity was assayed measuring the creatine
kinase (CK) levels in mice plasma (n ¼ 6, 20e25 g) after i.m.
injection of 50 ml of PBS (phosphate buffered saline) alone or PBS
containing 50 mg of Asp49 or Lys49 myotoxin, previously incubated
with aBaltMIP, into the right gastrocnemius muscle. CK activity was
assayed by the CKeUV kinetic kit (Bioclin, Brazil) as instructed by
the manufacturer. The activity was expressed in U/l, one unit cor-
responding to the production of 1 mmol of NADH per minute [40].
2.6. Circular dichroism spectroscopy
CD measurements were carried out in a JASCO model J-810 CD
spectropolarimeter equippedwith a peltier thermo-controllerwithin
a spectral range of 190e260 nm. The experimentswere performed at
20 C using an optical path-length of 1 mm with a 20 nm/min
scanning speed and response time of 2 s. Twenty spectra were
accumulated, averaged and corrected from the baseline for buffer
solution contribution and the resultant spectra were normalized to
residual molar ellipticity [q]. Samples (protein individually and
complexes) were analyzed in 5 mM phosphate buffer (pH 7.4) at
molar concentration of 10 mM. The enzyme/inhibitor complex was
prepared bymixing1:1M ratio, followedby incubation for 2 h at 4 C.
All solutions prior to experimentationwere centrifuged at 20,000 g
for 10 min to remove any aggregates and insoluble particles. Data
analysis and deconvolution were conducted using algorithms
implemented on the Dychroweb server [41].
2.7. Dynamic light scattering
The dynamic light scattering (DLS) measurements were per-
formedwith native aBaltMIP at 4 C (277 K) and 10 C (283 K) at the
concentration of 1.0 mg ml1 using a DynaPro TITAN equipment
(Wyatt Technology). The results were analyzed with the Dynamics
v.6.10 software. The data were measured one hundred times in
triplicate.
2.8. RNA extraction and cDNA synthesis
Approximately 120mg of frozen liver of B. alternatuswas ground
to a ﬁne powder with a mortar and pestle in the presence of liquid
nitrogen and used for total RNA isolation, following the guanidine
thiocyanate-Trizol method (Invitrogen, USA). RNA integrity was
analyzed by electrophoresis of 0.5e2 mg on a 1% agarose gel.
Electrophoresis was run at 100 V/cm using TBE (89 mM Tris base,
89 mM boric acid, 2 mM EDTA, pH 8.0) as the running buffer. The
gel was examined under UV light, in the presence of ethidium
bromide, for the presence of 18S and 28S bands corresponding to
ribosomal RNA. cDNA was synthesized from 2 to 5 mg of total RNA
by using a cDNA synthesis kit with oligo(dT)12e18 primer, in the
presence of dithiotreitol (First-Strand Synthesis kit, Invitrogen,
USA). PCR reactions were carried out with speciﬁc oligonucleotides
designed on the basis of the published nucleotide sequence
encoding for the aPLIs from Trimeresurus ﬂavoviridis [42]. Ampliﬁ-
cation conditions were 5 min at 94 C, 35 cycles of 3 min at 94 C,
30 s at 55 C and 30 s at 72 C, followed by an extension period of
7 min at 72 C (Perkin Elmer 2400 Thermocycler). A negative
control was carried out with no DNA. Aliquots of the ampliﬁcation
reaction were analyzed by electrophoresis on 1.0% agarose gels in
TBE buffer, in the presence of ethidium bromide.2.9. Cloning and cDNA sequence of aBaltMIP
Fresh PCR products were cloned in TA pCR 2.1 plasmid according
to manufacturer’s instructions (TA Cloning kit, Invitrogen, USA).
After transformation of Escherichia coli strain INVaF’ competent
cells, putative positive colonies were conﬁrmed by PCR with aPLIs
primers [42]. Five positive clones were randomly selected for
growth in liquid culture and the recombinant DNA was puriﬁed
using a commercial kit (Wizard Plus Minipreps, Promega, USA).
DNAs were completely sequenced by the dideoxy chain termina-
tion method (Sanger et al., 1977) on an automated ABI Prism 310
Genetic Analyser (Perkin Elmer Applied Biosystem, USA), using
M13 forward and M13 reverse oligonucleotides as primers in the
Big Dye Terminator Cycle sequencing Ready Reaction (Perkin Elmer
Applied Biosystems, CA, USA). The complete cDNA sequences were
deposited in the NCBI GenBank (EU421901 to EU421905).
2.10. Selection and alignment of homologous sequences
The sequences homologous to aBaltMIP were obtained from
NCBI database (http://www.ncbi.nlm.nih.gov) using the algorithm
BLASTP and a BLOSUM45 matrix. The multiple alignment between
aBaltMIP sequence and the selected homologue sequences was
executed by the program AMAP v.2.2 using default parameters [43].
2.11. Protein modeling
The crystallographic model of lung surfactant protein D (SP-D)
fromHomo sapiens (PDB code1pwb_chain A)was selected as the best
template for the building of the initial theoretical aBaltMIP structural
model, according to data obtained from the based-threadingmethod
programHHpred [44] (score¼ 203.9; e-value¼ 1.1e32), available at
the Max-Planck Institute for Developmental Biology server (http://
toolkit.tuebingen.mpg.de/hhpred). The initial theoretical aBaltMIP
structural model was generated by the programMODELLER 8v2 [45]
using the selected template.
2.12. Molecular dynamics simulation
The aBaltMIP model from program MODELLER 8v2 was
submitted to a molecular dynamics (MD) simulation executed by
the program GROMACS (Groningen Machine for Chemical Simula-
tion) v.4.0.2 [46,47] in presence of explicit water molecules [48],
using an Intel Core 2 Quad 64 equipped with an Ubuntu v.10.04
Linux operational system. Protonation states of charged groups
were set according to pH 7.0. Counter ions were added to neutralize
the system and the GROMOS 96 53a6 force ﬁeld [49] was chosen to
perform the MD simulation. The minimum distance between any
atom of the protein and the box wall was 1.0 nm. An energy
minimization (EM) using a steepest descent algorithm was per-
formed to generate the starting conﬁguration of the system. After
this step, 200 ps of MD simulation with position restraints applied
to the protein (PRMD) was executed in order to relax the system
gently. Then, 10 ns of unrestrained MD simulation were calculated
to evaluate the stability of the structures. All the MD simulations
were carried out in a periodic truncated dodecahedron box under
constant temperature (298 K) and pressure (1.0 bar) maintained by
the coupling to an external heat and an isotropic.
2.13. Evaluation of the theoretical aBaltMIP structural models and
assembling of the hypothetical oligomeric structure
Overall quality of all the theoretical aBaltMIP models obtained
after modeling, MD simulation, and simulated annealing reﬁnement
were checked with the programs RAMPAGE [50] and ProSA-web
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values of the backbone atoms fromtheﬁnalmonomericaBaltMIPMD
model were calculated and converted to B-factor values using the
programGROMACS v.4.0.2 [46,47]. The radii of gyration presented by
the aBaltMIP model during the MD simulation were also calculated
with the program GROMACS v.4.0.2. The assembling of the theoret-
ical trimeric aBaltMIP structure was performed with the program O
v.11.0.5 [52] by means of Ca atom alignments between the ﬁnal
aBaltMIP MD model and each one of the monomers of the trimeric
human lung surfactant protein D (SP-D). A simulated annealing
reﬁnement using the program CNS v.1.2 [53] was performed in order
to check the feasibility of the theoretical aBaltMIP trimer assembled
with the program O v.11.0.5.2.14. Statistical analysis
Results are presented as mean  S.D. obtained with the indi-
cated number of animals. The statistical signiﬁcance of differences
between groups was evaluated using Student’s unpaired t-test and
analysis of variance (ANOVA). A P value < 0.05 was considered to
indicate signiﬁcance.3. Results and discussion
In the present work, an a-type phospholipase A2 inhibitor (aPLI)
was puriﬁed from B. alternatus snake plasma by an afﬁnity chro-
matography using BthTX-I, a basic Lys49 PLA2, coupled on CNBr-
activated Sepharose 4B (Fig. 1A). In order to conﬁrm its purity
degree, the isolated aPLI, named aBaltMIP, was analyzed by
reverse-phase HPLC column and electrophoresis in presence of the
reducing agent b-mercaptoethanol (Fig. 1B). The inhibitor appeared
as a single polypeptide chain, showing to present a relative
molecular weight of 24,000 under reducing conditions (Fig. 1B).
Some other aPLIs were puriﬁed from a variety of snakes, as T. ﬂa-
voviridis [54], Agkistrodon blomhofﬁi [55], Atropoides nummifer [23],
Protobothrops ﬂavoviridis [24], Bothrops asper [32], Bothrops moojeni
[35] and B. jararacussu [25].Fig. 1. (A) Puriﬁcation of the a-type PLA2 inhibitor from Bothrops alternatus snake plasma. B.
applied on a CNBr-activated Sepharose chromatographic column, using a ﬂow rate of 2 ml/m
degree of aBaltMIP by 12% SDSePAGE (MMW-66,000; 45,000; 36,000; 29,000; 24,000
a concentration gradient of solvent B (0e100% of 70% acetonitrile plus 0.1% triﬂuoroaceticThe ability of aBaltMIP to inhibit phospholipase A2 and antico-
agulant activity was tested (Fig. 2A and B). The speciﬁc activity for
each PLA2 alone was considered as 100%. aBaltMIP was more
effective in inhibiting the PLA2 and anticoagulant activity of BthTX-
II and PrTX-III, showing to be less active against the activities
induced by crotoxin B and BthA-I-PLA2.
aBaltMIP inhibited between 38 and 41% of the enzymatic
activity of BthTX-II and PrTX-III, respectively, showing maximum
inhibition in the proportion of 1:1 PLA2/PLI (mol/mol) (Fig. 2A). It
has been reported that aPLIs isolated from American crotaline
snakes are more selective towards basic PLA2s [22,56], while those
of Asian species preferentially interact with acidic PLA2s [31].
Nevertheless, no evident differences in the amino acid sequences of
aPLIs could be ascribed to justify this variation in the inhibitory
proﬁles [56]. Quirós and co-workers [23] proposed that an intra
speciﬁc specialization of the inhibitor towards particular PLA2s
coevolving in its own venom would seem a more reasonable
explanation than an early subdivision of the speciﬁcity of these
inhibitors in Asian and American crotalines.
As previously mentioned, aBaltMIP presented higher anticoagu-
lant inhibition against BthTX-II and PrTX-III (Fig. 2B). A large number
of PLA2s from snake venoms display anticoagulant activity [57,58].
Some authors suggest that the capacity of PLA2s to bind and cleave
membrane phospholipids indicates that snake venom PLA2s inhibit
blood coagulation through the destruction of pro-coagulating phos-
pholipids, being the catalytic activity of PLA2s directly responsible for
its anticoagulant effects [59,60]. Our results corroborate with this
hypothesis, since anticoagulant and catalytic activity showed to be
similar.
aBaltMIP was also tested for its capacity in inhibiting PLA2
cytotoxicity, presenting high inhibition of the cytotoxicity (about
80%) induced by Lys49 PLA2s (BthTX-I and PrTX-I) (Fig. 2C). Some
studies involving Lys49 PLA2s have demonstrated that the
C-terminal region is related to the cytotoxic and bactericidal effects
of these proteins [61].
The myotoxicity induced by Bothrops Asp49 (BthTX-II and PrTX-
III) and Lys49 (BthTX-I and PrTX-I) PLA2s at an inhibitor:toxin molar
ratio of 0.4:1 showed that aBaltMIP presented a strong inhibition ofalternatus plasma (w10 ml) was diluted in 50 ml of 0.1 M phosphate buffer, pH 7.2 and
in. The inhibitor was eluted with 0.1 M Glycine-HCl, pH 2.8. (B) Evaluation of the purity
; 20,100; 14,200 and aBaltMIP Mr 24,000) and RP-HPLC using a C18 column and
acid).
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The total activity of each PLA2 alone was considered as 100%. Results are expressed as mean  S.D. (n ¼ 6).
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Asp49 PLA2s (Fig. 2D).
According to some authors, the main responsible for the toxic
effect in Lys49 PLA2s is the C-terminal region. This hypothesis could
be conﬁrmed by using synthetic peptides belonging to the
C-terminal region (amino acids 115e129), which was responsible
for the toxic activities of some myotoxic Lys49 PLA2s [62,63]. This
region combines cationic and hydrophobic amino acid residues
responsible for the damage mechanism of cellular membranes. The
cationic residues can interact with anionic groups of an acceptor
site, probably negatively loaded membrane phospholipids [63],
while the hydrophobic residues, especially the aromatic ones, can
interact with and possibly penetrate the phospholipid bilayer,
resulting in its destabilization [62]. However, the fact that a single
peptide plays all the main toxic activities of the origin molecule
does not prevent the existence of other motifs that can participate
or complement the action of the toxic effector site [63].In contrast, C-terminal peptides of some myotoxic Asp49 PLA2s
showed no membrane direct damage activity, suggesting that the
toxic mechanism exercised by these proteins probably involves its
catalytic activity as an important step, differently from that used by
myotoxic Lys49 PLA2s [62]. According to this hypothesis, some
studies have suggested that myotoxic Asp49 PLA2s may induce
muscle cell damage by affecting the integrity of plasmatic
membranes, thereby leading to hyper contraction and other
intracellular effects [13,64]. These membranes are formed by
different types of phospholipids, mainly phosphatidylcholine,
which can be hydrolyzed by Asp49 PLA2s producing free fatty acids
and lysophospholipids, causing cellular damage [13].
In order to bring some light to this discussion, the cytotoxic
activity was assayed upon mouse myoblast cell line (C2C12 cells),
testing BthTX-I (a Lys49myotoxin), pepBthTX-I (a synthetic peptide
derived from the C-terminal of BthTX-I) and aBaltMIP. The native
BthTX-I presented a high cytotoxicity on C2C12 cells, which was
Table 1
Data deconvolution of CB, BthTX-I, BthTX-II and their complexes with aBaltMIP,
using the CDSSTR method.
Helix Strand Turn Unordered Total
CB 0.39 0.14 0.19 0.27 0.99
BthTX-I 0.44 0.17 0.13 0.16 1.00
BthTX-II 0.54 0.12 0.14 0.20 1.00
aBaltMIP 0.50 0.13 0.16 0.22 1.01
Complex1 0.48 0.13 0.16 0.24 1.01
Complex2 0.60 0.15 0.11 0.14 1.00
Complex3 0.55 0.11 0.14 0.20 1.00
N.A. Santos-Filho et al. / Biochimie 93 (2011) 583e592588considered as 100%. The synthetic peptide pepBthTX-I also showed
cytotoxic activity against the evaluated cell line, even though this
activity was less signiﬁcant (about 76%). When aBaltMIP was
previously incubated with BthTX-I and pepBthTX-I, a remarkable
reduction on their cytotoxic activity was observed (about 40% of
activity to BthTX-I/aBaltMIP and 25% to pepBthTX-I/aBaltMIP, both
in the molar ratio of 1:1).
The C-terminal region of Lys49 PLA2s is possibly responsible for
the cytotoxic effect of these enzymes [61e63], and this hypothesis
was conﬁrmed by the present work. However, the participation of
other regions of the protein in the toxic mechanism cannot be
excluded. The interaction between inhibitor and protein (e.g.
aBaltMIP/BthTX-I) seems to occur in several ways and not only in
the C-terminal region, given that the toxic activity was not abol-
ished using C-terminal synthetic peptides.
As previously mentioned, aBaltMIP was able to inhibit both
Lys49 and Asp49 PLA2 myotoxic/cytotoxic activities, suggesting
there might be several ways of inhibition. Soares and co-workers
[35] suggested at least two mechanisms through which aPLIs could
neutralize PLA2s: (1) aPLIs could bind to PLA2 domains via its CRD
region and block, through steric hindrance, interaction between the
cytotoxic domain and the cell membrane or (2) aPLIs could directly
bind to other domains of myotoxins, avoiding direct contact with
the membrane.
Furthermore, the secondary structure contents of the Lys49
(BthTX-I) and Asp49 PLA2s (BthTX-II and CB), the inhibitor aBaltMIP
and their respective complexes were analyzed by CD spectroscopy.
All three PLA2s showed characteristic curves of helical proteins
featuring well-deﬁned peaks at 208 and 222 nm as expected for
a snake venom PLA2 structure (Fig. 3A). Analogously, the inhibitor
CD spectrum indicates a high content of helical structure elements
in its structure (Fig. 3A). CD spectra of the PLA2/inhibitor complexes
are considerably different from those corresponding to the indi-
vidual proteins (Fig. 3B, for more details, see Fig. 3C). Data decon-
volution suggests that the complexes had a relative gain of helical
structure elements in comparison to the individual protomers
(Table 1), which may indicate a more compact structure upon
complexation.
The N-terminal sequence of aBaltMIP, comprising the ﬁrst 31
amino acid residues, was determined by automatic sequencing
using the Edman degradation method, showing the sequence
HEQDPDGKLLNSLIDALMHLQREFAKLRGAF. The comparison of the
N-terminal sequence of aBaltMIP and an amino acid sequence81 0 091 02 0 012
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Fig. 3. Far UV-CD spectra for aBaltMIP, PLA2s and association of PLI/PLA2. Spectra for CB, B
aBaltMIP (B); for more details graph (C) presents only BthTX-I and aBaltMIP at a 1:1 M ratdeduced from cDNA of an aPLI from B. alternatus (EU421904.1)
showed 100% of identity. The deduced mature sequence shows 147
residues, presenting the conserved cysteine residues at positions
64, 119, 133 and 141, and the putative glycosylation site at N103,
characteristic of aPLIs (Fig. 4).
Additionally, in an attempt to obtain insights into the structural
features of aBaltMIP, a theoretical three-dimensional structure of
aBaltMIP was constructed using a threading modeling technique
and improved by a 10 ns molecular dynamics (MD) simulation
[44e47]. The initial theoretical aBaltMIP structural model calcu-
lated by the programMODELLER 8v2 showed a good stereochemical
conﬁguration, with 99.3% of its amino acid residues in the favoured
and allowed regions of Ramachandran plot [50]. Furthermore, the
residues of the initial theoretical aBaltMIP structural model have
also presented an adequate overall quality (Z-score ¼ 4.43) in
comparison with experimentally-determined native proteins of
similar size deposited in the Protein Data Bank (PDB) [51]. The
structural characteristics of the initial model are kept in the theo-
retical aBaltMIP model obtained after a 10 ns molecular dynamics
simulation, which presents 97.9% of its residues distributed in the
favoured and allowed regions of Ramachandran plot [50] and also
an overall good quality (Z-score ¼ 4.99) [51]. The analysis of the
overall aBaltMIP structure calculated after the MD simulation
showed the twomain structural features of aPLIs were conserved at
theﬁnalmodel: the a-helical neck and the carbohydrate recognition
domain (CRD), whose main secondary structural elements are two
a-helices and ﬁve b-strains (Fig. 5A).
The comparison of the deduced amino acid sequence of aBaltMIP
with other snake aPLIs e including the theoretical model of GbPLIa
(an aPLI from Gloydius brevicaudus) [65] e and SP-D proteins from
H. sapiens and Rattus norvegicus shows the mammal amino acid022 032 042 52 0 062 072
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Fig. 4. cDNA and amino acid sequence of a phospholipase A2 inhibitor from Bothrops alternatus snake plasma (EU421904.1). The underlined amino acids correspond to the
N-terminal peptide, which was determined by chemical sequencing of the puriﬁed aBaltMIP. The mature polypeptide chain presents 147 amino acid residues.
N.A. Santos-Filho et al. / Biochimie 93 (2011) 583e592 589sequences present an insertion in the 97e109 region (correspond-
ing to 294e306 region according to the human sequence numera-
tion) (Fig. 6). Interestingly, a structural comparison between the
ﬁnal aBaltMIP MD model and the SP-D crystallographic structure
from H. sapiens indicates this insertion that corresponds to a loop
where the residues Asp297 and Glu301 are placed, which are
involved in the coordination of two Ca2þ ions (Fig. 6). One of these
Ca2þ ions is also responsible for coordination of important structural
elements (a loop and another Ca2þ ion) involved in carbohydrate
binding [66]. Therefore, the absence of this “Ca2þ-binding” loop in
the aBaltMIP theoretical model seems to strengthen the hypothesis
that snake aPLIs do not bind to carbohydrates and present a Ca2þ-
independent inhibitory activity, as previously observed byOkumuraFig. 5. (A) Cartoon representation of the ﬁnal theoretical aBaltMIP model obtained after a
correspond, respectively, to the a-helical neck region and carbohydrate recognition domain (
it is preserved in all snake aPLI sequences. Illustration generated by the program PyMOL v.1
model calculated by the program GROMACS v.4.0.2 [46,47]. The vertical line separates the a-
high ﬂexibility presented by the ﬁrst segment in comparison to the second during the MDet al. [65]. In this same work, it was also stated that the a-helical
neck regions of snake aPLIs lead to trimerization of these proteins,
resulting in the formation of a central pore responsible for binding
and inhibition of PLA2s. Indeed, the dynamic light scattering (DLS)
experiments carried out with the puriﬁed aBaltMIP strengthen the
possible importance of oligomerization for this protein and,
possibly, for other snake aPLIs. The DLS data showed aBaltMIP
presents a narrow unimodal size distribution at 4 C (277 K) and
10 C (283 K), with, respectively, polidispersity values of 3.3% and
13.4% and mean hydrodynamic radii (RH) of 3.4 nm and 3.6 nm.
Remarkably, the RH values of the scattering centers formed in the
tested conditions are considerably distinct from the radius of
gyration values (w2.0e2.5 nm) presented by the aBaltMIP model10 ns molecular dynamics (MD) simulation [46,47]. The residues 11e37 and 49e143
CRD); the residue Asn103 (stick representation) corresponds to a glycosylation site and
.0 [67]. (B) Average backbone atom RMSF values of the ﬁnal monomeric aBaltMIP MD
helical neck region from the carbohydrate recognition domain (CRD) to emphasize the
simulation.
Fig. 6. Multiple alignment between the amino acid sequences of aBaltMIP and other snake aPLI sequences and mammalian lung surfactant proteins D (SP-D) generated with the
program AMAP v.2.2 [43]. All the sequences were obtained in the NCBI protein database. aPLIs: Bothrops alternatus (gi:215275473); Bothrops erythromelas (gi:215275474); Bothrops
neuwiedi (gi:218546740); Bothrops jararaca (gi:215275475); Bothrops jararacussu (gi:167547115); Bothrops moojeni (gi:218546738); Gloydius blomhofﬁi siniticus (gi:6467183);
Lachesis muta (gi:218546736); Trimeresurus ﬂavoviridis (gi:160357989); Elaphe quadrivirgata (gi:82133672). Mammalian lung surfactant proteins D (SP-D): Rattus norvegicus
(gi:39654792); Homo sapiens (gi:34810883).
Fig. 7. Hypothetical aBaltMIP trimeric assembling obtained after a simulated annealing reﬁnement [52,53]. The three aBaltMIP monomers ﬁtted well in a trimeric spherical
arrangement whose maximum dimensions (about 7.5 nm) indicate that the approximate radius of the oligomer is quite close to the broader RH value (3.6 nm) calculated in the DLS
experiments at 10 C. It is also possible to observe a slightly twist between the a-helical neck regions, suggesting the probable importance of these regions for the oligomeric
assembling. Illustration generated by the program PyMOL v.1.0 [67].
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was performed with a single monomer, a trimeric oligomer was
assembled and submitted to a simulated annealing reﬁnement
[52,53] in order to check speciﬁcally if aBaltMIP could also trimerize
like other snake aPLIs, as proposed byOkumura et al. [65]. The result
of this simulated annealing reﬁnement showed the three aBaltMIP
monomers ﬁtted well in a spherical trimeric arrangement whose
approximate radius (3.75 nm) is quite close to the RH value (3.6 nm)
calculated in the DLS experiments at 10 C (Fig. 7). Another inter-
esting feature about the theoretical aBaltMIP trimeric model was
a noticeable twist between the a-helical neck regions of the model,
thus indicating these parts of the molecule may play an important
role in trimerization. Interestingly, the rootmean square ﬂuctuation
(RMSF) of the backbone atoms from a-helical necks during the MD
simulation indicates these regions are highly ﬂexible in relation to
other segments of themonomericmolecule (Fig. 5B). This structural
feature becomes more evident when the RMSF of each aBaltMIP
backbone atom is converted into a B-factor value: the backbone
atoms of the a-helical neck region present an average B-factor
around 1096.9 Å2, whereas the overall B-factor average is approxi-
mately 467.4 Å2 [46,47]. Consequently, a possible aBaltMIP trimeric
arrangement held by tight interactions between the a-helical neck
regions could present the additional beneﬁt of avoiding potential
unfavorable contacts of these segmentswith unspeciﬁc PLA2 sites in
a complex whose molar ratio was 1:1. Otherwise, the circular
dichroism (CD) trials have showed that the aBaltMIP/PLA2 complex
is probably more compact in relation to the separated protomers
due to the relative increase of helical segments in relation to the
separated protomers. This ﬁnding indicates that the PLA2 binding
could even induce structural modiﬁcations in aBaltMIP and other
aPLI protomers to optimize and/or accelerate the formation of
intricate inhibitory complexes as that suggested here (formed by
one trimeric aPLI oligomer and one PLA2molecule). Such hypothesis
seems reasonably probable when it is taken into account that the
concentration of aPLIs in the snake tissues must be far lower in
comparison to the conditions of the experimental procedures per-
formed with the puriﬁed aBaltMIP.Acknowledgements
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